Compare CCB & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCB | NVAX |
|---|---|---|
| Founded | 1997 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2018 | 1996 |
| Metric | CCB | NVAX |
|---|---|---|
| Price | $45.96 | $10.07 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $126.67 | $11.33 |
| AVG Volume (30 Days) | 144.5K | ★ 5.3M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $96.61 | N/A |
| Revenue Next Year | $22.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $36.61 | $6.20 |
| 52 Week High | $120.05 | $11.85 |
| Indicator | CCB | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 60.72 |
| Support Level | $45.60 | $9.12 |
| Resistance Level | $50.78 | $10.36 |
| Average True Range (ATR) | 1.89 | 0.62 |
| MACD | 0.33 | -0.03 |
| Stochastic Oscillator | 16.78 | 54.53 |
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.